Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells

References

• Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003;63(6):1311–1316.
   PubMed Web of Science ®Google Scholar
• Murata T, Haisa M, Uetsuka F, Nobuhisa T, Ookawa T, Tabuchi Y, et al. Molecular mechanism of chemoresistance to cisplatin in ovarian cancer cell lines. Int. J. Mol. Med. 2004;13(6):865–868.
   PubMed Web of Science ®Google Scholar
• Kim EY, Kim A, Kim SK, Chang YS. AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. Cancer Lett. 2015;358(1):85–91.
   PubMed Web of Science ®Google Scholar
• O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical Status of cisplatin, carboplatin, and other platinum-based antitumor drugs. In: B Lippert, Ed. Cisplatin Chemistry and Biochemistry of a Leading Anticancer Drug. Basel, Switzerland:Verlag-CH; 1999:31–69.
   Google Scholar
• Molina JR, Yang P, Cassivi SD, Schild SE. Non-small lung Cancer: epidemiology, risk factors, treatment, and survivorship. Symp. Solid Tumors 2008;83(5):584–594.
   Google Scholar
• Sharp SY, Rogers PM, Kelland LR. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexyl-amine platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance. Clin. Cancer Res. 1995;1(9):981–989.
   PubMed Web of Science ®Google Scholar
• Sherman SE, Lippard SJ. Structural aspects of platinum abti-cancer drug-interaction with DNA. Chem. Rev. 1987;87(5):1153–1181.
   Web of Science ®Google Scholar
• Pascoe JM, Roberts JJ. Interactions between mammalian-cell DNA and inorganic platinum compounds. 1. DNA interstrand crosslinking and cytotoxic properties of platimun (II) compounds. Biochem. Pharmacol. 1974;23(9):1345–1357.
   PubMed Web of Science ®Google Scholar
• Speelmans G, Sips W, Grisel RJH, Staffhorst R, Fichtinger Schepman AMJ, Reedijk J, et al. The interaction of the anti-cancer drug cisplatin with phospholipids is specific for negatively charged phospholipids and rakes place at low chloride ion concentration. Biochimica Et Biophysica Acta Biomembr. 1996;1283(1):60–66.
   PubMed Web of Science ®Google Scholar
• Zamble DB, Lippard SJ. Cisplatin and DNA-repair in cancer-chemotherapy. Trends Biochem. Sci. 1995;20(10):435–439.
   PubMed Web of Science ®Google Scholar
• Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 1998;34(10):1535–1542.
   PubMed Web of Science ®Google Scholar
• Reedijk J. New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc. Natl. Acad. Sci. USA 2003;100(7):3611–3616.
   PubMed Web of Science ®Google Scholar
• Garattini S, La Vecchia C. Perspectives in cancer chemotherapy. Eur. J. Cancer 2001;37:S128–S147.
   Google Scholar
• Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: An historical perspective and an update. Eur. J. Cancer 1998;34(10):1522–1534.
   PubMed Web of Science ®Google Scholar
• Ferguson LR, Pearson AE. The clinical use of mutagenic anticancer drugs. Mutation Res. Fundam. Mol. Mech. Mutagen. 1996;355(1–2):1–12.
   PubMed Web of Science ®Google Scholar
• Ekborn A, Laurell G, Johnstrom P, Wallin I, Eksborg S, Ehrsson H. D-Methionine and cisplatin ototoxicity in the guinea pig: D-methionine influences cisplatin pharmacokinetics. Hear. Res. 2002;165(1–2):53–61.
   PubMed Web of Science ®Google Scholar
• Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: Current status. Cancer Treat. Rev. 2004;30(1):53–81.
   PubMed Web of Science ®Google Scholar
• Deconti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum(II). Cancer Res. 1973;33(6):1310–1315.
   PubMed Web of Science ®Google Scholar
• Boulikas T. Molecular mechanisms of cisplatin and its liposomally encapsulated form, Lipoplatin. Lipoplatin as a chemotherapy and antiangiogenesis drug. Cancer Ther. 2007;5:351–376.
   Google Scholar
• Boulikas T. Low toxicity and anticancer activity of a novel liposomal cisplatin (Lipoplatin) in mouse xenografts. Oncol. Rep. 2004;12(1):3–12.
   PubMed Web of Science ®Google Scholar
• Devarajan P, Tarabishi R, Mishra J, Ma Q, Kourvetaris A, Vougiouka M, et al. Low renal toxicity of lipoplatin compared to cisplatin in animals. Anticancer Res. 2004;24(4):2193–2200.
   PubMed Web of Science ®Google Scholar
• Boulikas T, Stathopoulos GP, Volakakis N, Vougiouka M. Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res. 2005;25(4):3031–3039.
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG. Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study. Oncol. Rep. 2006;15(5):1201–1204.
   PubMed Web of Science ®Google Scholar
• Charest G, Paquette B, Fortin D, Mathieu D, Sanche L. Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation. J. Neuro. Oncol. 2010;97(2):187–193.
   PubMed Web of Science ®Google Scholar
• Walker-Daniels J, Coffman K, Azimi M, Rhim JS, Bostwick DG, Snyder P, Kerns BJ, Waters DJ, Kinch MS. Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate 1999;41(4):275–280.
   PubMed Web of Science ®Google Scholar
• Ogawa K, Pasqualini R, Lindberg RA, Kain R, Freeman AL, Pasquale EB. The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene 2000;19(52):6043–6052.
   PubMed Web of Science ®Google Scholar
• Nakamoto M, Bergemann AD. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc. Res. Tech. 2002;59(1):58–67.
   PubMed Web of Science ®Google Scholar
• Nasreen N, Mohammed KA, Lai Y, Antony VB. Receptor EphA2 activation with ephrinA1 suppresses growth of malignant mesothelioma (MM). Cancer Lett. 2007;258(2):215–222.
   PubMed Web of Science ®Google Scholar
• Han LQ, Dong ZM, Qiao YH, Kristensen GB, Holm R, Nesland JM, et al. The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol. Oncol. 2005;99(2):278–286.
   PubMed Web of Science ®Google Scholar
• Hafner C, Schmitz G, Meyer S, Bataille F, Hau P, Langmann T, Dietmaier W, Landthaler M, Vogt T. Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin. Chem. 2004;50(3):490–499.
   PubMed Web of Science ®Google Scholar
• Nakamura R, Kataoka H, Sato N, Kanamori M, Ihara M, Igarashi H, et al. EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci. 2005;96(1):42–47.
   PubMed Web of Science ®Google Scholar
• Xu F, Zhong W, LiJ C, Zhang SS, Cui JC, Nesland JM, et al. Predictive value of EphA2 and EphrinA-1 expression in oesophageal squamous cell carcinoma. Anticancer Res. 2005;25(4):2943–2950.
   PubMed Web of Science ®Google Scholar
• Mohammed KA, Wang X, Goldberg EP, Antony VB, Nasreen N. Silencing receptor EphA2 induces apoptosis and attenuates tumor growth in malignant mesothelioma. Am. J. Cancer Res. 2011;1(3):419–431.
   PubMed Web of Science ®Google Scholar
• Nasreen N, Mohammed KA, Antony VB. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006;107(10):2425–2435.
   PubMed Web of Science ®Google Scholar
• Yuan W, Chen Z, Wu S, Guo J, Ge J, Yang P, et al. Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo. Neoplasma 2012;59(1):105–113.
   PubMed Web of Science ®Google Scholar
• Landen CN, Jr., Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005;65(15):6910–6918.
   PubMed Web of Science ®Google Scholar
• Macrae M, Neve RM, Rodriguez-Viciana P, Haqq C, Yeh J, Chen C, et al. A conditional feedback loop regulates Ras activity through EphA2. Cancer Cell 2005;8(2):111–118.
   PubMed Web of Science ®Google Scholar
• Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 2010;10(3):165–180.
   PubMed Web of Science ®Google Scholar
• Lee HY, Mohammed KA, Kaye F, Sharma P, Moudgil BM, Clapp WL, et al. Targeted delivery of let-7a microRNA encapsulated ephrin-A1 conjugated liposomal nanoparticles inhibit tumor growth in lung cancer. Int. J. Nanomed. 2013;8:4481–4494.
   PubMed Web of Science ®Google Scholar
• Khodayari N, Mohammed KA, Goldberg EP, Nasreen N. EphrinA1 inhibits malignant mesothelioma tumor growth via let-7 microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther. 2011;18(11):806–816.
   PubMed Web of Science ®Google Scholar
• Nasreen N, Khodayari N, Sriram PS, Patel J, Mohammed KA. Tobacco smoke induces epithelial barrier dysfunction via receptor EphA2 signaling. Am. J. Physiol. Cell Physiol. 2014;306(12):C1154–C1166.
   Google Scholar
• Wang X, Guo Z. Targeting and delivery of platinum-based anticancer drugs. Chem. Soc. Rev. 2013;42(1):202–224.
   PubMed Web of Science ®Google Scholar
• Butler JS, Sadler PJ. Targeted delivery of platinum-based anticancer complexes. Curr. Opin. Chem. Biol. 2013;17(2):175–188.
   PubMed Web of Science ®Google Scholar
• Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, et al. A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours. Br. J. Cancer 2011;104(4):593–598.
   PubMed Web of Science ®Google Scholar
• Preiss MR, Bothun GD. Stimuli-responsive liposome-nanoparticle assemblies. Expert Opin. Drug Deliv. 2011;8(8):1025–1040.
   PubMed Web of Science ®Google Scholar
• Song L, Coppola D, Livingston S, Cress D, Haura EB. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 2005;4(3):267–276.
   PubMed Web of Science ®Google Scholar
• Woessmann W, Chen X, Borkhardt A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother. Pharmacol. 2002;50(5):397–404.
   PubMed Web of Science ®Google Scholar
• Messina S, Leonetti C, De Gregorio G, Affatigato V, Ragona G, Frati L, et al. Ras inhibition amplifies cisplatin sensitivity of human glioblastoma. Biochem. Biophys. Res. Commun. 2004;320(2):493–500.
   PubMed Web of Science ®Google Scholar
• Yeddula N, Xia Y, Ke E, Beumer J, Verma IM. Screening for tumor suppressors: loss of ephrin receptor A2 cooperates with oncogenic KRas in promoting lung adenocarcinoma. Proc. Natl. Acad. Sci. USA 2015;112(47):E6476–E6485.
   PubMed Web of Science ®Google Scholar
• Brannan JM, Sen B, Saigal B, Prudkin L, Behrens C, Solis L, et al. EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev. Res. 2009;2(12):1039–1049.
   PubMed Web of Science ®Google Scholar
• Mott JL, Kobayashi S, Bronk SF, Gores GJ. Mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007;26(42):6133–6140.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B. The biochemistry of programmed cell death. FASEB J. 1995;9(13):1277–1287.
   PubMed Web of Science ®Google Scholar